Feature rEVO Biologics spearheading preeclampsia treatment By Len Zehr Closely held rEVO Biologics is enrolling patients in a Phase 3 clinical trial of its ATryn recombinant human antithrombin for the treatment of early-onset preeclampsia, with top-line data expected in the... November 11, 2014